Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Protara Therapeutics Inc.

Insiders have been trading these 5 stocks: (($QURE)), (($TARA)), (($ABEO)), (($CBRS)) and (($VRSN)). Here is a breakdown of their recent trades and...

uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeu...

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA)

Protara Therapeutics ( ($TARA) ) has issued an announcement. On June 26, 2026, Protara Therapeutics, Inc. announced that Chief Medical Officer Leon...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARA	$4.28	+1.79%	743.92K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TARA	$4.28	+1.8%	743.92K
3
4
5
6

TARA

TARA

Get Protara Therapeutics Inc. Data in Excel

Get Protara Therapeutics Inc. Data in Excel